294 related articles for article (PubMed ID: 21451508)
1. Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma.
Mürdter TE; Schroth W; Bacchus-Gerybadze L; Winter S; Heinkele G; Simon W; Fasching PA; Fehm T; ; Eichelbaum M; Schwab M; Brauch H
Clin Pharmacol Ther; 2011 May; 89(5):708-17. PubMed ID: 21451508
[TBL] [Abstract][Full Text] [Related]
2. Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patients.
Lim JS; Chen XA; Singh O; Yap YS; Ng RC; Wong NS; Wong M; Lee EJ; Chowbay B
Br J Clin Pharmacol; 2011 May; 71(5):737-50. PubMed ID: 21480951
[TBL] [Abstract][Full Text] [Related]
3. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment.
Jin Y; Desta Z; Stearns V; Ward B; Ho H; Lee KH; Skaar T; Storniolo AM; Li L; Araba A; Blanchard R; Nguyen A; Ullmer L; Hayden J; Lemler S; Weinshilboum RM; Rae JM; Hayes DF; Flockhart DA
J Natl Cancer Inst; 2005 Jan; 97(1):30-9. PubMed ID: 15632378
[TBL] [Abstract][Full Text] [Related]
4. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes.
Schroth W; Antoniadou L; Fritz P; Schwab M; Muerdter T; Zanger UM; Simon W; Eichelbaum M; Brauch H
J Clin Oncol; 2007 Nov; 25(33):5187-93. PubMed ID: 18024866
[TBL] [Abstract][Full Text] [Related]
5. Limited predictive value of achieving beneficial plasma (Z)-endoxifen threshold level by CYP2D6 genotyping in tamoxifen-treated Polish women with breast cancer.
Hennig EE; Piatkowska M; Karczmarski J; Goryca K; Brewczynska E; Jazwiec R; Kluska A; Omiotek R; Paziewska A; Dadlez M; Ostrowski J
BMC Cancer; 2015 Aug; 15():570. PubMed ID: 26232141
[TBL] [Abstract][Full Text] [Related]
6. Impacts of the Glucuronidase Genotypes UGT1A4, UGT2B7, UGT2B15 and UGT2B17 on Tamoxifen Metabolism in Breast Cancer Patients.
Romero-Lorca A; Novillo A; Gaibar M; Bandrés F; Fernández-Santander A
PLoS One; 2015; 10(7):e0132269. PubMed ID: 26176234
[TBL] [Abstract][Full Text] [Related]
7. Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer.
Gjerde J; Geisler J; Lundgren S; Ekse D; Varhaug JE; Mellgren G; Steen VM; Lien EA
BMC Cancer; 2010 Jun; 10():313. PubMed ID: 20565970
[TBL] [Abstract][Full Text] [Related]
8. Multigene and Drug Interaction Approach for Tamoxifen Metabolite Patterns Reveals Possible Involvement of CYP2C9, CYP2C19, and ABCB1.
Powers JL; Buys SS; Fletcher D; Melis R; Johnson-Davis KL; Lyon E; Malmberg EM; McMillin GA
J Clin Pharmacol; 2016 Dec; 56(12):1570-1581. PubMed ID: 27198207
[TBL] [Abstract][Full Text] [Related]
9. The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver.
Coller JK; Krebsfaenger N; Klein K; Endrizzi K; Wolbold R; Lang T; Nüssler A; Neuhaus P; Zanger UM; Eichelbaum M; Mürdter TE
Br J Clin Pharmacol; 2002 Aug; 54(2):157-67. PubMed ID: 12207635
[TBL] [Abstract][Full Text] [Related]
10. Pharmacogenetics of UGT1A4, UGT2B7 and UGT2B15 and Their Influence on Tamoxifen Disposition in Asian Breast Cancer Patients.
Sutiman N; Lim JSL; Muerdter TE; Singh O; Cheung YB; Ng RCH; Yap YS; Wong NS; Ang PCS; Dent R; Schroth W; Schwab M; Khor CC; Chowbay B
Clin Pharmacokinet; 2016 Oct; 55(10):1239-1250. PubMed ID: 27098059
[TBL] [Abstract][Full Text] [Related]
11. Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer.
Wegman P; Elingarami S; Carstensen J; Stål O; Nordenskjöld B; Wingren S
Breast Cancer Res; 2007; 9(1):R7. PubMed ID: 17244352
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenomics of tamoxifen therapy.
Brauch H; Mürdter TE; Eichelbaum M; Schwab M
Clin Chem; 2009 Oct; 55(10):1770-82. PubMed ID: 19574470
[TBL] [Abstract][Full Text] [Related]
13. The formation of estrogen-like tamoxifen metabolites and their influence on enzyme activity and gene expression of ADME genes.
Johänning J; Kröner P; Thomas M; Zanger UM; Nörenberg A; Eichelbaum M; Schwab M; Brauch H; Schroth W; Mürdter TE
Arch Toxicol; 2018 Mar; 92(3):1099-1112. PubMed ID: 29285606
[TBL] [Abstract][Full Text] [Related]
14. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment.
Borges S; Desta Z; Li L; Skaar TC; Ward BA; Nguyen A; Jin Y; Storniolo AM; Nikoloff DM; Wu L; Hillman G; Hayes DF; Stearns V; Flockhart DA
Clin Pharmacol Ther; 2006 Jul; 80(1):61-74. PubMed ID: 16815318
[TBL] [Abstract][Full Text] [Related]
15. CYP3A4 and seasonal variation in vitamin D status in addition to CYP2D6 contribute to therapeutic endoxifen level during tamoxifen therapy.
Teft WA; Gong IY; Dingle B; Potvin K; Younus J; Vandenberg TA; Brackstone M; Perera FE; Choi YH; Zou G; Legan RM; Tirona RG; Kim RB
Breast Cancer Res Treat; 2013 May; 139(1):95-105. PubMed ID: 23580071
[TBL] [Abstract][Full Text] [Related]
16. Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers.
Kirchheiner J; Meineke I; Müller G; Roots I; Brockmöller J
Pharmacogenetics; 2002 Oct; 12(7):571-80. PubMed ID: 12360109
[TBL] [Abstract][Full Text] [Related]
17. Hormonal status affects plasma exposure of tamoxifen and its main metabolites in tamoxifen-treated breast cancer patients.
Ximenez JPB; de Andrade JM; Marques MP; Coelho EB; Suarez-Kurtz G; Lanchote VL
BMC Pharmacol Toxicol; 2019 Dec; 20(Suppl 1):81. PubMed ID: 31852530
[TBL] [Abstract][Full Text] [Related]
18. The Influences of Adherence to Tamoxifen and CYP2D6 Pharmacogenetics on Plasma Concentrations of the Active Metabolite (Z)-Endoxifen in Breast Cancer.
Nardin JM; Schroth W; Almeida TA; Mürdter T; Picolotto S; Vendramini ECL; Hoppe R; Kogin JP; Miqueleto D; de Moraes SDR; Schwab M; Pecoits-Filho RF; Brauch H; Casali-da-Rocha JC
Clin Transl Sci; 2020 Mar; 13(2):284-292. PubMed ID: 31573754
[TBL] [Abstract][Full Text] [Related]
19. Influence of CYP2D6 polymorphisms on serum levels of tamoxifen metabolites in Spanish women with breast cancer.
Zafra-Ceres M; de Haro T; Farez-Vidal E; Blancas I; Bandres F; de Dueñas EM; Ochoa-Aranda E; Gomez-Capilla JA; Gomez-Llorente C
Int J Med Sci; 2013; 10(7):932-7. PubMed ID: 23781139
[TBL] [Abstract][Full Text] [Related]
20. Relationship between genotypes Sult1a2 and Cyp2d6 and tamoxifen metabolism in breast cancer patients.
Fernández-Santander A; Gaibar M; Novillo A; Romero-Lorca A; Rubio M; Chicharro LM; Tejerina A; Bandrés F
PLoS One; 2013; 8(7):e70183. PubMed ID: 23922954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
